8.7817

0.96% 0.0717

Phathom Pharmaceuticals Inc (PHAT)

Overview News Price History Option Chain Financials Discussions Forecast

Phathom Pharmaceuticals Inc stock is traded at $8.7817, with a volume of 428.64K. It is up +0.96% in the last 24 hours and down -51.87% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Previous Close:

$8.71

Open:

$8.68

24h Volume:

428.64K

Relative Volume:

0.34

Market Cap:

$599.26M

Revenue:

Net Income/Loss:

$-297.11M

P/E Ratio:

-2.005

EPS:

-4.38

Net Cash Flow:

$-216.95M

1W Performance:

-1.97%

1M Performance:

-51.87%

6M Performance:

-14.88%

1Y Performance:

+20.45%

1-Day Range:

$8.60

$9.18

1-Week Range:

$8.51

$9.18

52-Week Range:

$6.065

$19.71

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name

Phathom Pharmaceuticals Inc

Sector

Healthcare (1180)

Industry

Biotechnology (683)

Phone

(877) 742-8466

Address

100 CAMPUS DRIVE,, FLORHAM PARK, NJ

Employee

112

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PHAT's Discussions on Twitter

Compare PHAT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHAT Phathom Pharmaceuticals Inc	8.79	599.26M	0	-297.11M	-216.95M	-5.19
VRTX Vertex Pharmaceuticals Inc	461.00	119.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	752.71	82.77B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.63	37.02B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	251.43	32.26B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.19	28.24B	3.30B	-501.07M	1.03B	-2.1146

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-03-24	Initiated	Stifel	Buy
Jan-05-24	Reiterated	Needham	Buy
Aug-09-23	Initiated	H.C. Wainwright	Buy
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral
Feb-17-21	Initiated	BMO Capital Markets	Outperform
Feb-02-21	Initiated	Guggenheim	Buy
Jun-26-20	Downgrade	Goldman	Neutral → Sell
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Goldman	Neutral
Nov-19-19	Initiated	Jefferies	Buy
Nov-19-19	Initiated	Needham	Buy

View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

Dec 01, 2024

Wasatch Advisors LP Buys Shares of 246,942 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat

Dec 01, 2024

Nov 30, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.5%Should You Sell? - MarketBeat

Nov 30, 2024

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Short Interest Update - MarketBeat

Nov 30, 2024

Nov 25, 2024

Eagle Asset Management Inc. Increases Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat

Nov 25, 2024

(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 25, 2024

Nov 23, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownTime to Sell? - MarketBeat

Nov 23, 2024

Nov 21, 2024

Jennison Associates LLC Has $106.06 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat

Nov 21, 2024

Nov 20, 2024

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know - MSN

Nov 20, 2024

Nov 19, 2024

Phathom Pharmaceuticals - The Healthcare Technology Report.

Nov 19, 2024

Nov 14, 2024

(PHAT) Proactive Strategies - Stock Traders Daily

Nov 14, 2024

Nov 11, 2024

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 11, 2024

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Up 115.60% This Year: What Is Going To Happen Next - Stocks Register

Nov 11, 2024

Phathom Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Business Updates - Defense World

Nov 11, 2024

Nov 09, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.9%Here's What Happened - MarketBeat

Nov 09, 2024

Nov 08, 2024